Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA.
Bioorg Med Chem Lett. 2010 Mar 15;20(6):1913-7. doi: 10.1016/j.bmcl.2010.01.154. Epub 2010 Feb 4.
We report SAR studies on a novel non-peptidic bombesin receptor subtype-3 (BRS-3) agonist lead series derived from high-throughput screening hit RY-337. This effort led to the discovery of compound 22e with significantly improved potency at both rodent and human BRS-3.
我们报告了一项新型非肽类炸弹素受体亚型 3(BRS-3)激动剂先导系列的 SAR 研究,该系列源自高通量筛选的命中化合物 RY-337。这项工作发现了化合物 22e,其对啮齿动物和人类 BRS-3 的活性显著提高。